Bryan Fitzgerald, PharmD, BCOP

Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.

Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.

Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.

Clinicians cite long-term complications and younger patients with better prognoses as reasons to pull back on oropharyngeal cancer therapy.

Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer